Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

European Heart Journal

7 April 2021
Organised by: Logo
ESC Journals VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Myocardial Disease

Abstract

Abstract

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.

Contributors

Pablo Garcia-Pavia
Pablo Garcia-Pavia

Author

Hospital Universitario Puerta de Hierro Majadahonda Majadahonda , Spain

Antonio Brucato
Antonio Brucato

Author

University of Milan Milan , Italy

Alida L P Caforio
Alida L P Caforio

Author

University of Padua Padova , Italy

Thibaud Damy
Thibaud Damy

Author

University Hospital Henri Mondor Creteil , France

Julian D Gillmore
Julian D Gillmore

Author

UCL Greater London , United Kingdom of Great Britain & Northern Ireland

Massimo Imazio
Massimo Imazio

Author

University Hospital Santa Maria della Misericordia Udine , Italy

ESC 365 is supported by